Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 206
- 试验地点
- 1
- 主要终点
- Current use of advanced therapy
研究概览
简要总结
A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance.
This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years of age
- •Confirmed diagnosis of IBD (CD, UC or indeterminate colitis)
- •Willing to provide consent for participation
- •Managed at an outpatient clinic either the Yale New Haven Hospital system or the University of Texas at Austin Hospital system.
排除标准
- •Patients <18
- •No confirmed diagnosis of IBD
- •Not planning to continue care at either study site (i.e. presenting for a consultation only)
- •Unwilling to provide signed consent
结局指标
主要结局
Current use of advanced therapy
时间窗: baseline
Use of or prescription of a biologic or small molecule therapy to treat inflammatory bowel disease
次要结局
- IBD-related disease complications(12 months)
研究者
Linda Anne Feagins, MD
Associate Professor of Medicine
University of Texas at Austin